Skip to main content
Caliway logo

Caliway — Investor Relations & Filings

Ticker · 6919 ISIN · TW0006919004 LEI · 984500D2D587B98A7B13 TW Professional, scientific and technical activities
Open in API
Filings indexed 56 across all filing types
Latest filing 2026-05-22 Notice of Dividend Amou…
Country TW Taiwan
Listing TW 6919

About Caliway

www.caliwaybiopharma.com

Caliway Biopharmaceuticals Co., Ltd. is a clinical-stage company specializing in the discovery and development of small-molecule therapeutics for medical aesthetics and chronic inflammatory diseases. The company focuses on high-value markets with significant unmet medical needs, utilizing unique pharmacological mechanisms to create niche products. Its lead candidate, CBL-514, is a first-in-class injectable drug designed to induce adipocyte apoptosis for non-surgical local fat reduction, cellulite, and the treatment of Dercum’s disease. Other pipeline assets include CBA-539, a long-acting injectable for pigmentation and anti-aging, and CBF-520, which targets central obesity and visceral fat reduction. Caliway aims to redefine aesthetic medicine and inflammatory disease management through innovative, non-invasive treatments that offer improved safety and efficacy over existing therapies.

Recent filings

Filing Released Lang Actions
114年第4季股利金額(董事會決議)
Notice of Dividend Amount Classification · 89% confidence The document is a dividend distribution schedule (“公司股利分派情形”) showing board resolutions, shareholders’ meeting confirmations, per-share cash dividend amounts, record dates and related dividend policies. This matches a Notice of Dividend Amount rather than a full financial report or subsidiary filing. Thus it is classified as a dividend announcement.
2026-05-22 Chinese
公司治理組織架構
Governance Information Classification · 90% confidence The document is a table from Taiwan’s public disclosure system detailing the company's board composition, director terms, independent directors, vacancies, and committee setups (audit, remuneration) as well as governance-related information such as legal counsel and shareholder suggestion handling. This aligns with internal governance structure details rather than a report or announcement of financials, votes, or transactions. Therefore, it fits the “Governance Information” category (CGR).
2026-05-22 Chinese
本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之第二個多 國多中心樞紐三期臨床試驗CBL-0302申請，今日已完成澳洲主管 機關HREC送件
Regulatory Filings Classification · 88% confidence The document is a regulatory disclosure on a Taiwanese Market Observation Post System, detailing the company’s submission of a Phase III clinical trial application for a new drug. It contains no financial statements, earnings data, management changes, or voting results, and is clearly an announcement of a material event rather than a corporate report. It therefore falls under the general Regulatory Filings (RNS) category.
2026-05-20 Chinese
本公司受邀參加由台新證券舉辦之「台新2026年第二季全球投資論壇」
Regulatory Filings Classification · 75% confidence The document is a public information filing on Taiwan’s Market Observation Post System (公開資訊觀測站) announcing the date, time, and venue for an upcoming investor conference (“法人說明會”) where the company will present operational updates. It does not contain actual financial statements or slides, nor is it a proxy, dividend, or voting result notice. It is a general regulatory announcement required by stock exchange rules and falls into the fallback category for miscellaneous compliance filings.
2026-05-20 Chinese
115年05月法人說明會簡報
Regulatory Filings Classification · 80% confidence The document is a listing from the public information site showing the schedule, location, and brief description of an institutional investor meeting (“法人說明會”). It contains no substantive presentation slides or financial data—only an event announcement stating that materials will be posted after the meeting. This is a general regulatory notification rather than an actual investor presentation file, earnings release, or annual/interim report. It therefore falls into the miscellaneous “Regulatory Filings” category.
2026-05-20 Chinese
本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之亞太二期 臨床試驗CBL-0206，今日台灣TFDA已核准執行
Regulatory Filings Classification · 92% confidence The document is a material fact announcement filed to the public information observatory (“公開資訊觀測站”) by company 6919 regarding TFDA approval of a Phase 2 clinical trial for its new drug. It does not present financial statements, dividend details, management changes, or earnings results, but is a regulatory announcement of a non‐financial event. Therefore, it falls under the generic “Regulatory Filings” category (RNS).
2026-05-19 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.